Everest Expands Ophthalmology Portfolio in China - Summary - MDSpire

Everest Expands Ophthalmology Portfolio in China

Everest Medicines acquires rights to presbyopia eye drop

June 15, 2026
2 min

The Ophthalmologist

Share

Objective:

To develop, manufacture, and commercialize LNZ100, a prescription eye drop for presbyopia, across Greater China.

Approach:

Key Findings:

LNZ100 is designed to improve near vision without overstimulating the ciliary muscle.
The drug was well tolerated with no serious treatment-related adverse events reported.
Presbyopia prevalence in China reaches nearly 100% by age 52, with limited current treatment options.

Interpretation:

Limitations:

No drug is currently approved for presbyopia in China.
Current treatment options are limited to glasses and invasive surgery.

Conclusion:

Everest's transaction aims to expand its ophthalmology portfolio and strengthen business synergies.

Sources:

PR Newswire

Original Source(s)

The Ophthalmologist

Everest Expands Ophthalmology Portfolio in China

June 15, 2026

Related Content

The Ophthalmologist

Shape-Changing IOL Shows Durability

Atia Vision reports positive 36-month data for its shape-changing IOL at ASCRS 2026

April 28, 2026
3 min

Ophthalmic Professional

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

July 8, 2025
2 min

Ophthalmology Management

The Latest News in Ophthalmology

A look at the latest news in ophthalmology

September 1, 2025
11 min